These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24367555)

  • 1. Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: a decision analysis.
    van't Hoog AH; Cobelens F; Vassall A; van Kampen S; Dorman SE; Alland D; Ellner J
    PLoS One; 2013; 8(12):e82786. PubMed ID: 24367555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
    Vassall A; van Kampen S; Sohn H; Michael JS; John KR; den Boon S; Davis JL; Whitelaw A; Nicol MP; Gler MT; Khaliqov A; Zamudio C; Perkins MD; Boehme CC; Cobelens F
    PLoS Med; 2011 Nov; 8(11):e1001120. PubMed ID: 22087078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.
    Walusimbi S; Kwesiga B; Rodrigues R; Haile M; de Costa A; Bogg L; Katamba A
    BMC Health Serv Res; 2016 Oct; 16(1):563. PubMed ID: 27724908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa.
    Gupta-Wright A; Ha H; Abdulgadar S; Crowder R; Emmanuel J; Mukwatamundu J; Marcelo D; Phillips PPJ; Christopher DJ; Nhung NV; Theron G; Yu C; Nahid P; Cattamanchi A; Worodria W; Denkinger CM;
    Lancet Glob Health; 2024 Feb; 12(2):e226-e234. PubMed ID: 38245113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of GeneXpert Omni compared with GeneXpert MTB/Rif for point-of-care diagnosis of tuberculosis in a low-resource, high-burden setting in Eastern Uganda: a cost-effectiveness analysis based on decision analytical modelling.
    Ejalu DL; Irioko A; Kirabo R; Mukose AD; Ekirapa E; Kagaayi J; Namutundu J
    BMJ Open; 2022 Aug; 12(8):e059823. PubMed ID: 35998960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert
    Pallas SW; Courey M; Hy C; Killam WP; Warren D; Moore B
    Appl Health Econ Health Policy; 2018 Aug; 16(4):537-548. PubMed ID: 29862440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis.
    Jha S; Ismail N; Clark D; Lewis JJ; Omar S; Dreyer A; Chihota V; Churchyard G; Dowdy DW
    PLoS One; 2016; 11(6):e0157554. PubMed ID: 27322162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of different Xpert MTB/Rif implementation strategies in programmatic settings at the regional referral hospitals in Uganda: Evidence for country wide roll out.
    Muttamba W; Ssengooba W; Sekibira R; Kirenga B; Katamba A; Joloba M
    PLoS One; 2018; 13(3):e0194741. PubMed ID: 29566056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated chest-radiography as a triage for Xpert testing in resource-constrained settings: a prospective study of diagnostic accuracy and costs.
    Philipsen RH; Sánchez CI; Maduskar P; Melendez J; Peters-Bax L; Peter JG; Dawson R; Theron G; Dheda K; van Ginneken B
    Sci Rep; 2015 Jul; 5():12215. PubMed ID: 26212560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States.
    Choi HW; Miele K; Dowdy D; Shah M
    Int J Tuberc Lung Dis; 2013 Oct; 17(10):1328-35. PubMed ID: 24025386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
    Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
    PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicomponent strategy with decentralised molecular testing for tuberculosis in Uganda: a cost and cost-effectiveness analysis.
    Thompson RR; Nalugwa T; Oyuku D; Tucker A; Nantale M; Nakaweesa A; Musinguzi J; Reza TF; Zimmer AJ; Ferguson O; Turyahabwe S; Joloba M; Cattamanchi A; Katamba A; Dowdy DW; Sohn H
    Lancet Glob Health; 2023 Feb; 11(2):e278-e286. PubMed ID: 36669808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in children: a prospective, multi-centre evaluation.
    Reither K; Manyama C; Clowes P; Rachow A; Mapamba D; Steiner A; Ross A; Mfinanga E; Sasamalo M; Nsubuga M; Aloi F; Cirillo D; Jugheli L; Lwilla F
    J Infect; 2015 Apr; 70(4):392-9. PubMed ID: 25312863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis.
    Brümmer LE; Thompson RR; Malhotra A; Shrestha S; Kendall EA; Andrews JR; Phillips P; Nahid P; Cattamanchi A; Marx FM; Denkinger CM; Dowdy DW
    Clin Infect Dis; 2024 Jan; 78(1):154-163. PubMed ID: 37623745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?
    Theron G; Pooran A; Peter J; van Zyl-Smit R; Kumar Mishra H; Meldau R; Calligaro G; Allwood B; Sharma SK; Dawson R; Dheda K
    Eur Respir J; 2012 Jul; 40(1):161-8. PubMed ID: 22075479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensified tuberculosis case-finding in HIV-positive adults managed at Ethiopian health centers: diagnostic yield of Xpert MTB/RIF compared with smear microscopy and liquid culture.
    Balcha TT; Sturegård E; Winqvist N; Skogmar S; Reepalu A; Jemal ZH; Tibesso G; Schön T; Björkman P
    PLoS One; 2014; 9(1):e85478. PubMed ID: 24465572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.